An interventional study of Interscalene Nerve Block and Anterior suprascapular nerve block in Postoperative Pain, Acute, sponsored by ASST Sette Laghi. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-21.
Sponsored by ASST Sette Laghi · Not applicable, Interventional, and Treatment
Among 115 studies in Pain, Postoperative with a site in Italy — 18 open to participants now, 21 under way, none of them phase 3. Pain, Postoperative · Italy.
Among the 115 studies in Pain, Postoperative with a site in Italy, this one is the 30th largest by planned enrollment of the 86 interventional ones that give a count, is one of 3 that started in 2026, is one of 63 with no phase, reaches primary completion later than 15 of the 20 other live ones, and was the 115th registered.
5,640 studies on the registry are indexed under Pain, Postoperative; 1,230 are open to participants now.
Browse Pain, Postoperative studies →18 of the 115 studies in Pain, Postoperative with a site in Italy are open now. Recruiting first, the newest first:
University of Rome Tor Vergata · Sites in Italy
ASST Gaetano Pini-CTO · Sites in Italy
A.O.U. Città della Salute e della Scienza · Sites in Italy
AUSL Romagna Rimini · Sites in Italy
Vittore Buzzi Children's Hospital · Sites in Italy
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 679 Pain, Postoperative studies recruiting now, 241 (35%) set no upper age limit and 328 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
115 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 5 · Phase 3 7 · Phase 4 11
First in 2006; this study’s year is marked. 3 started in 2026.
This study's planned enrollment of 100 is above the median of 75 across 4,821 interventional studies indexed under Pain, Postoperative.
Median enrollment 79 across the 86 interventional studies, 120 across the 29 observational. Of the 71 that completed or were terminated, 6 (8%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 115 have an industry lead sponsor. The 10 most frequent:
ASST Sette Laghi is the lead sponsor of 4 studies on the registry; 4 are open to participants now.
ASST Sette Laghi has 1 study filed under Pain, Postoperative — fewer than ten, so there is no comparison to draw.
6 of the studies in Pain, Postoperative with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06182059Policlinico di Monza SpAPersistent Post Surgical Pain After Total Knee Arthroplasty | 2027-01-31 |
| NCT07831096ASST Sette LaghiAnterior Suprascapular Versus Interscalene Block for Postoperative Analgesia After Arthroscopic Shoulder Surgery in the Outpatient Setting | 2027-02 |
| NCT06244732IRCCS Policlinico S. DonatoPain Control After Aortic EndoaneurYsmEctomy (POPEYE) | 2027-02 |
| NCT07239817ASST Gaetano Pini-CTOPENG Block + LIA For Endoprosthesis Surgery | 2027-02-28 |
| NCT07250373Fondazione Policlinico Universitario Agostino Gemelli IRCCSSerratus Posterior Superior Intercostal Plane (SPSIP) Block Versus Intercostal Nerve (ICN) Block in Patients Undergoing Uniportal-VATS. | 2027-04-30 |
Among the 115 studies in Pain, Postoperative with a site in Italy, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Shoulder surgery performed in the outpatient setting can be associated with moderate to severe postoperative pain, especially during the first hours after surgery. Regional anesthesia is commonly used to improve postoperative pain control, reduce opioid use, and support early recovery and safe discharge.
The interscalene block (ISB) is widely considered an effective regional anesthesia technique for shoulder surgery, but it may be associated with adverse effects such as diaphragmatic impairment, dyspnea, hoarseness, Horner syndrome, and prolonged upper limb motor block. The anterior suprascapular nerve block (SSNB-A) is a more selective regional anesthesia technique that may provide comparable postoperative analgesia with fewer block-related adverse effects.
This prospective, randomized, single-blind, noninferiority trial compares SSNB-A with ISB in adult patients undergoing unilateral shoulder surgery in the outpatient setting. All participants receive general anesthesia and the same multimodal analgesic strategy. The primary objective is to determine whether SSNB-A is noninferior to ISB for postoperative pain control, assessed using the Numeric Rating Scale (NRS). Secondary outcomes include quality of recovery measured with the QoR-15 questionnaire, block-related adverse events, sensory and motor block characteristics, and the need for rescue analgesic medication.
Shoulder surgery in the outpatient setting requires an anesthetic and analgesic strategy that provides effective postoperative pain control while allowing early recovery and safe discharge. Unilateral shoulder procedures may be associated with moderate to severe postoperative pain, particularly during the first 24 to 48 hours after surgery. In this context, regional anesthesia is an important component of perioperative pain management because it can reduce postoperative pain, decrease the need for opioid analgesics, limit postoperative nausea and vomiting, and facilitate early rehabilitation and recovery.
The interscalene brachial plexus block (ISB) is commonly used for postoperative analgesia after shoulder surgery and is considered one of the most effective regional anesthesia techniques for this indication. However, ISB may be associated with block-related adverse effects, including variable phrenic nerve involvement with diaphragmatic impairment, dyspnea, Horner syndrome, hoarseness, and prolonged motor block of the upper limb. These effects may be particularly relevant in the outpatient setting, where delayed discharge, unplanned admission, or reduced quality of recovery may occur if adverse effects persist after surgery.
The anterior suprascapular nerve block (SSNB-A) has been proposed as a regional anesthesia technique for shoulder surgery that may provide effective analgesia while potentially reducing some of the adverse effects associated with ISB. The suprascapular nerve contributes substantially to the sensory innervation of the shoulder. The anterior approach targets the nerve in the supraclavicular region and may also allow local anesthetic spread toward relevant components of the superior trunk region involved in shoulder innervation. Available evidence suggests that SSNB-A may provide postoperative analgesia comparable to ISB in selected shoulder procedures, with a potentially more favorable side-effect profile.
This study is a prospective, monocentric, randomized, single-blind, noninferiority trial comparing SSNB-A with ISB for postoperative analgesia in adult patients undergoing unilateral shoulder surgery in the outpatient setting. Participants are randomized to receive either an ultrasound-guided interscalene block or an ultrasound-guided anterior suprascapular nerve block before surgery. Randomization is performed shortly before the procedure using block randomization in order to ensure balanced allocation between the two study groups.
Eligible participants are adult patients scheduled for unilateral shoulder surgery in the outpatient setting under general anesthesia. Surgical procedures may include long head of biceps tenotomy, biceps anchor repair, Bankart procedure, rotator cuff repair with or without biological membrane augmentation, subacromial decompression, acromioplasty, and acromioclavicular stabilization. Participants are screened according to predefined inclusion and exclusion criteria. Exclusion criteria include contraindications to regional anesthesia, allergy to local anesthetics or study analgesic drugs, known neuropathy or sensory or motor deficits in the surgical area or block territory, severe obesity, severe chronic obstructive pulmonary disease, pregnancy, known phrenic nerve paralysis with diaphragmatic paralysis, chronic opioid use, severe chronic pain, and inability or unwillingness to follow the postoperative analgesic protocol.
Both regional anesthesia techniques are routinely used at the study center and are performed by anesthesiologists experienced in ultrasound-guided upper limb nerve blocks. In the ISB group, the block is performed with the patient in the supine or semi-sitting position, with the head turned away from the surgical side. The brachial plexus is identified between the anterior and middle scalene muscles at the level of the cricoid cartilage using a linear ultrasound probe. An echogenic 21-gauge needle is advanced with an in-plane technique toward the space between the C5 and C6 nerve roots. After negative aspiration, 10 mL of ropivacaine 0.5% is injected in divided boluses to obtain adequate local anesthetic spread.
In the SSNB-A group, the block is performed with the patient in the supine or semi-sitting position, with the head turned away from the surgical side. The superior trunk of the brachial plexus is identified using a linear ultrasound probe, and the suprascapular nerve is visualized in the supraclavicular fossa as it separates from the superior trunk and courses beneath the inferior belly of the omohyoid muscle. An echogenic 21-gauge needle is advanced with an in-plane technique toward the suprascapular nerve. After negative aspiration, 10 mL of ropivacaine 0.5% is injected in divided boluses to obtain adequate spread around the nerve.
All participants undergo general anesthesia according to the study protocol. Intraoperative monitoring includes oxygen saturation, heart rate, noninvasive blood pressure, 5-lead electrocardiography, bispectral index monitoring, end-tidal carbon dioxide, and body temperature. Dexamethasone 0.15 mg/kg is administered intravenously before surgical incision. General anesthesia is maintained with inhaled anesthetics and opioids. Before the end of surgery, paracetamol 15 mg/kg and ondansetron 0.1 mg/kg are administered according to the protocol. After emergence from anesthesia, participants are observed in the post-anesthesia care unit.
Postoperative analgesia is standardized in both study groups. In the post-anesthesia care unit, if postoperative pain is rated as NRS 4 or higher, ketorolac 30 mg intravenously is administered as first-line rescue analgesia. If pain remains uncontrolled after 30 minutes, tramadol 1 mg/kg intravenously is administered as second-line rescue analgesia. Participants are discharged from the post-anesthesia care unit to the day surgery ward when Aldrete discharge criteria are met. During the day surgery stay, participants continue the standardized recovery pathway, including monitoring of vital signs, pain control, mobilization, oral intake, hydration, and spontaneous urination. Additional postoperative analgesia during the ward stay includes oral paracetamol and ibuprofen as rescue therapy according to the study protocol.
At discharge, participants receive instructions for the postoperative multimodal analgesic regimen and the data collection forms. Post-discharge follow-up is performed by telephone at predefined time points in order to assess pain control, adherence to the analgesic regimen, recovery, adverse events, and outcome measures. Quality of recovery is assessed using the QoR-15 questionnaire during follow-up. Postoperative pain is assessed using the Numeric Rating Scale at predefined time points after surgery.
The primary objective of the study is to determine whether SSNB-A is noninferior to ISB in terms of postoperative pain control after shoulder surgery in the outpatient setting. The primary endpoint is postoperative pain measured by the Numeric Rating Scale, with the main analysis focused on the NRS score at 6 hours after surgery. The noninferiority margin is defined as 1.1 points on the 0-to-10 NRS scale.
Secondary objectives include comparison of block-related adverse events, including dyspnea, oxygen desaturation, hoarseness, Horner syndrome, pneumothorax, and neurologic complications; assessment of quality of recovery using the QoR-15 questionnaire at discharge and during postoperative follow-up up to postoperative day 5 and at 30 days; comparison of sensory and motor block characteristics in the relevant dermatomes and myotomes; and comparison of rescue analgesic use within a standardized multimodal analgesic protocol.
Baseline demographic and clinical data are collected before the anesthetic procedures, including age, sex, weight, height, ASA physical status, previous surgery, allergies, current medications, and relevant medical history. Intraoperative and postoperative data are collected according to the study protocol. Participants and postoperative outcome assessors are blinded to group allocation, while the anesthesiologist performing the block is not blinded. Statistical analyses are planned before completion of data collection and are performed by an investigator blinded to treatment allocation.
The planned sample size is 100 participants. The sample size calculation is based on the primary noninferiority analysis of postoperative NRS pain scores, assuming a noninferiority margin of 1.1, an estimated standard deviation of 2, a one-sided type I error rate of 5%, and a type II error rate below 20%. The sample size is increased to account for protocol deviations and exclusions, as the primary analysis is planned according to a per-protocol approach.
The study is conducted in accordance with the principles of Good Clinical Practice, the Declaration of Helsinki, and applicable national and international regulations regarding personal data protection. Written informed consent is obtained from all participants before enrollment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants randomized to this group receive an ultrasound-guided interscalene brachial plexus block before shoulder surgery, followed by standardized general anesthesia and the same multimodal postoperative analgesic protocol used in both study groups.
Procedure: Interscalene Nerve Block · Drug: Ropivacaine
Participants randomized to this group receive an ultrasound-guided anterior suprascapular nerve block before shoulder surgery, followed by standardized general anesthesia and the same multimodal postoperative analgesic protocol used in both study groups.
Procedure: Anterior suprascapular nerve block · Drug: Ropivacaine
Participants receive an ultrasound-guided interscalene brachial plexus block before shoulder surgery using 10 mL of ropivacaina 0,5%, followed bu standardized general anesthesia and postoperative multimodal analgesia
Also known as: Ultrasound-guided interscalene block, ISB
Participants receive an ultrasound-guided anterior suprascapular nerve block before shoulder surgery using 10 mL of ropivacaine 0,5%, followed by standardized general anesthesia and postoperative multimodal analgesia.
Also known as: SSNB-A, Ultrasound-guided anterior suprascapular nerve block
Ropivacaine 0.5% is used as the local anesthetic for the assigned ultrasound-guided regional anesthesia procedure. Participants receive 10 mL of ropivacaine 0.5% either for interscalene brachial plexus block or for anterior suprascapular nerve block, according to randomized group allocation. The same drug concentration and volume are used in both study groups.
Also known as: Ropivacaine 0.5%
Postoperative pain intensity at 6 hours after surgery
Postoperative pain intensity assessed using the Numeric Rating Scale (NRS), where 0 indicates no pain and 10 indicates the worst imaginable pain. The primary analysis compares NRS pain scores between the anterior suprascapular nerve block group and the interscalene block group to assess noninferiority.
Time frame: 6 hours after surgery
Postoperative Pain Intensity at Other Predefined Postoperative Time Points
Postoperative pain intensity assessed using the Numeric Rating Scale (NRS), where 0 indicates no pain and 10 indicates the worst imaginable pain, at predefined postoperative time points other than the primary 6-hour endpoint
Time frame: At post-anesthesia care unit arrival and at 12, 18, 24, 36, 48, and 72 hours after surgery
Quality of Recovery
Quality of recovery assessed using the 15-item Quality of Recovery questionnaire (QoR-15). The QoR-15 is a patient-reported outcome measure evaluating postoperative recovery across multiple domains, including pain, physical comfort, physical independence, psychological support, and emotional state. Higher scores indicate better quality of recovery. Scores will be compared between the two study groups at predefined postoperative time points.
Time frame: On postoperative day 0, postoperative day 1, postoperative day 2, postoperative day 3, and postoperative day 5
Incidence of Block-Related Adverse Events
Incidence of adverse events potentially related to the regional anesthesia technique, including dyspnea, oxygen desaturation, hoarseness, Horner syndrome, pneumothorax, and neurologic complications. The incidence of these events will be compared between the anterior suprascapular nerve block group and the interscalene block group.
Time frame: From block performance through postoperative day 0
Rescue Analgesic Consumption
Use of rescue analgesic medication for uncontrolled postoperative pain within the standardized multimodal analgesic protocol. During the postoperative hospital stay, first-line rescue analgesia consists of nonsteroidal anti-inflammatory drugs and second-line rescue analgesia consists of opioid analgesics. After discharge, rescue analgesic use includes dexibuprofen 400 mg as first-line rescue medication and tapentadol 50 mg as second-line rescue medication. For each rescue analgesic administration or intake, the timing and the NRS pain score at the time of use will be recorded. Rescue analgesic consumption will be compared between the anterior suprascapular nerve block group and the interscalene block group.
Time frame: From post-anesthesia care unit arrival through postoperative day 5
Sensory and Motor Block Characteristics
Sensory and motor block characteristics assessed after regional anesthesia in the relevant nerve territories. Sensory and motor function will be evaluated in C5, C6, C7, C8, T1, and superior trunk territory using a 3-point scale, where 2 indicates normal sensation or motor function, 1 indicates reduced sensation or motor function, and 0 indicates absent sensation or motor function. The extent, onset, and persistence of sensory and motor block will be compared between the anterior suprascapular nerve block group and the interscalene block group.
Time frame: At 30 minutes after block performance, at post-anesthesia care unit arrival, and 6 hours after surgery
Plan to share: Undecided — Individual participant data will not be shared. Study results may be published in aggregate and fully anonymized form. Information allowing participant identification will remain confidential and will not be disclosed outside the study center, except for authorized monitoring or regulatory purposes as allowed by applicable laws and consent procedures.
Started Jan 2026 (actual). Primary completion is estimated for Feb 2027, 13 months after the start.
Of 2,089 non-industry interventional studies with no phase under Pain, Postoperative, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's planned 13 months is above that.
Counting every sponsor, half of 2,102 studies reached it within 11 months; a quarter within 6 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
ASST Sette Laghi